Tag: TAK-003
Takeda’s dengue vaccine candidate granted priority review by US-FDA
TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age
Takeda’s dengue vaccine candidate shows positive results during 4.5 years long...
TAK-003 was generally well tolerated, and there were no important safety risks identified. No evidence of disease enhancement was observed over the 54-month follow-up exploratory analysis